Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran cardiovascular outcomes study in established cardiovascular disease
PACTR202201515851137Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of inclisiran, sponsored by Novartis. Started Nov 2021; status: recruiting.
02
Drugs
inclisiran
Beyond the preview
Go deeper on PACTR202201515851137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201515851137.